About My Health Careers Internship MedBlogs Contact us

Adcetris Will Continue to Lead the Pack in Hodgkin’s Lymphoma Market: Expert

by Vishnuprasad on December 21, 2015 at 6:15 PM
Font : A-A+

 Adcetris Will Continue to Lead the Pack in Hodgkin’s Lymphoma Market: Expert

Seattle Genetics/Takeda's Adcetris to treat Hodgkin's lymphoma, cancer of the lymph nodes, will continue to lead the market in the United States, opines an analyst with research and consulting firm GlobalData.

According to Stelios Tzellos, Ph.D., GlobalData's Analyst covering Oncology and Hematology, the medicine is likely to gain swift popularity following its anticipated label extension in Europe from early 2016.


Tzellos says the therapy was lauded at the recent 2015 American Society of Hematology (ASH) Meeting and Exposition held in Orlando, Florida.

"Adcetris, a CD30-targeting agent, demonstrated a remarkable increase in progression-free survival (PFS) compared with placebo in the new post-autologous transplantation setting. Data presented at ASH indicated that the median PFS was not reached in the Adcetris-treatment arm, while it was less than 16 months in the placebo arm. GlobalData expects that these new data will propel Adcetris towards regulatory approval in Europe in early 2016, leading to its rapid uptake in the Hodgkin's lymphoma treatment space. The size of the Adcetris target patient population will expand, and Seattle Genetics hopes this will support its goal to establish the therapy as the foundation of care for Hodgkin's lymphoma," Tzellos explains.

Meanwhile, Bristol-Myers Squibb (BMS) and Merck and Co., will race to bring their anti-PD-1 therapies to the Hodgkin's lymphoma arena. The two major pharmaceutical companies presented clinical trial data at ASH. Also, BMS's Opdivo is slightly better than Merck's Keytruda in terms of clinical efficacy.

"Although Adcetris will surely gain dominance in its field due to its ability to induce durable remission and long-term survival in heavily pre-treated relapsed and refractory Hodgkin's lymphoma patients, Seattle Genetics is taking steps to fend off competition from the two oncology juggernauts. For example, the company is collaborating with BMS to investigate the combination of Adcetris and Opdivo in the salvage setting of relapsed and refractory Hodgkin's lymphoma patients who fail standard front-line chemotherapy. With Seattle Genetics also evaluating the combination of Adcetris with Treanda in the same setting, GlobalData believes the company has chosen a successful strategy to stay ahead in the Hodgkin's lymphoma treatment space," Tzellos adds.

Source: Medindia

News A-Z
News Category
What's New on Medindia
Breast Cancer Awareness Month 2021 - It's time to RISE
First-Ever Successful Pig-To-Human Kidney Transplantation
World Osteoporosis Day 2021 -
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Chronic Lymphocytic Leukemia AIDS-HIV-Cancer Bone Marrow Transplantation 

Recommended Reading
Gastrointestinal Stromal Tumors may Lead to Cancers Outside Their Syndromes
Patients with GST are more likely to develop other sarcomas, melanoma, colorectal, esophageal, ......
Childhood Cancer Survivors Face Increased Second Cancer Risk, Earlier Death
Survivors of childhood cancer in Australia are at an increased risk of second cancers and an ......
Pancreas Cancer Liquid Biopsy Flows from Blood-Borne Packets
Conducting biopsies during treatment would more closely monitor therapy success or failure and help ...
Mental Health Status Prior to Bladder Cancer Surgery Influences Postoperative Outcomes
Patients whose self-assessment of mental health was low suffered more high grade complications in .....
AIDS defining malignancies are cancers that occur in patients with AIDS due to their low immunity....
Bone Marrow Transplantation
Preferred Term is Hematopoietic stem cell transplantation. In this stem cell from bone marrow are in...
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL) is one of the most common types of adult leukemia and is consider...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use